Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Dalfampridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dalfampridine SCHEMBL3845825 | 1.00 | — | — | |
| Dalfampridine SCHEMBL53483 | 0.96 | — | — | |
| Dalfampridine SCHEMBL1442620 | 0.96 | MAPT (1.00) | — | |
| Dalfampridine SCHEMBL7987482 | 0.93 | — | — | |
| Dalfampridine SCHEMBL28757299 | 0.93 | MAPT (0.93) | — | |
| Dalfampridine SCHEMBL28976215 | 0.93 | — | — | |
| Dalfampridine SCHEMBL8968143 | 0.93 | — | — | |
| Dalfampridine SCHEMBL31012422 | 0.93 | — | — | |
| Dalfampridine SCHEMBL7113651 | 0.93 | — | — | |
| Dalfampridine SCHEMBL28750367 | 0.93 | MAPT (0.93) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0945496-B1 | Ink compositions and multicolor thermal ink jet printing process for the production of high quality images | XEROX CORP (US) | 2003-11-12 | — | — | EP | claimed |
| EP-0945496-A1 | Ink compositions and multicolor thermal ink jet printing process for the production of high quality images | Xerox Corporation (US) | 1999-09-29 | — | — | EP | claimed |
| US-5958121-A | SET OF INKS COMPRISING FIRST AQUEOUS INK CONSISTING OF ANIONIC COLORANT, SECOND AQUEOUS INK CONTAINING AMMONIUM SALT, WHEREIN FIRST COLORANT IS IMMOBILIZED ON SUBSTRATE BY INTERACTION WITH AMMONIUM SALT, REDUCING INTERCOLOR BLEED | XEROX CORPORATION (US) | 1999-09-28 | — | — | US | claimed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-110650951-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-110650951-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-0945496-B1 | Ink compositions and multicolor thermal ink jet printing process for the production of high quality images | XEROX CORP (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-0945496-A1 | Ink compositions and multicolor thermal ink jet printing process for the production of high quality images | Xerox Corporation (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5958121-A | SET OF INKS COMPRISING FIRST AQUEOUS INK CONSISTING OF ANIONIC COLORANT, SECOND AQUEOUS INK CONTAINING AMMONIUM SALT, WHEREIN FIRST COLORANT IS IMMOBILIZED ON SUBSTRATE BY INTERACTION WITH AMMONIUM SALT, REDUCING INTERCOLOR BLEED | XEROX CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999043681-A1 | 4-(4-PIPERIDYLMETHYLAMINO) SUBSTITUTED HETEROARYL FUSED PYRIDINES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-09-02 | — | — | WO | disclosed |